Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-1123a in Subjects With Advanced Solid Tumors

NCT02690337 is registered in ClinicalTrials.gov with Daiichi Sankyo Co., Ltd. as lead sponsor.

NCT NCT02690337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02690337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-1123a in Subjects With Advanced Solid Tumors
Lead sponsor
Daiichi Sankyo Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2016
Completion date
November 30, 2017
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignant tumors